Immunome reports Q2 EPS (50c), consensus (50c)

Reports Q2 revenue $4.01M, consensus $1.02M. As of June 30, 2025, cash, cash equivalents and marketable securities totaled $268.0M. Immunome (IMNM) expects its current cash position to fund operations into 2027. “Immunome made substantial progress in Q2, underscored by the continued advancement of our clinical programs towards key milestones,” said CEO Clay Siegall. “We look forward to sharing topline data for the RINGSIDE trial of varegacestat before the end of this year, and we are well-positioned to support a new drug application submission for that program as appropriate. We recently dosed the third cohort of patients in the dose escalation study of IM-1021, our ROR1 ADC. We are excited by the profile of HC74, the proprietary TOP1 inhibitor payload contained in IM-1021, and are making progress towards IND submission for three additional ADCs utilizing that technology.”